학술논문
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Clinical Research Article
Clinical Research Article
Document Type
Academic Journal
Author
Source
Journal of the Endocrine Society. December 2023, Vol. 7 Issue 12
Subject
Language
English
ISSN
2472-1972
Abstract
GH deficiency (GHD) is the most common endocrine deficit complicated by pituitary tumors [1] and is known to cause metabolic complications, such as obesity, dyslipidemia [2], and fatty liver [3], [...]
Context: GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective: We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods: We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results: Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P< .001) and significantly correlated with the peak GH (r = -0.50, P< .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels ([beta] = -0.345; 95% CI, -0.533 to -0.158) and the lowest quartile of the peak GH ( Conclusion: The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP. Key Words: hypopituitarism, inflammation, pituitary neuroendocrine tumor, Rathke's cleft cyst
Context: GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective: We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods: We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results: Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P< .001) and significantly correlated with the peak GH (r = -0.50, P< .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels ([beta] = -0.345; 95% CI, -0.533 to -0.158) and the lowest quartile of the peak GH ( Conclusion: The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP. Key Words: hypopituitarism, inflammation, pituitary neuroendocrine tumor, Rathke's cleft cyst